BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 30078497)

  • 41. Genomics of chronic neutrophilic leukemia.
    Maxson JE; Tyner JW
    Blood; 2017 Feb; 129(6):715-722. PubMed ID: 28028025
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Guest Editorial: Understanding of MPN and MDS/MPN based on molecular pathogenesis and clinical aspects.
    Harada H
    Int J Hematol; 2017 Jun; 105(6):709-710. PubMed ID: 28447249
    [No Abstract]   [Full Text] [Related]  

  • 43. A case of atypical chronic myeloid leukemia regarded as MDS with myeloproliferative features.
    Tohda S; Koyama N; Tanaka M; Kida Y; Murakami N; Nara N
    Acta Haematol; 1998; 100(4):191-4. PubMed ID: 9973641
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allogeneic hematopoietic stem cell transplant in adult patients with myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap syndromes.
    Sharma P; Shinde SS; Damlaj M; Hefazi Rorghabeh M; Hashmi SK; Litzow MR; Hogan WJ; Gangat N; Elliott MA; Al-Kali A; Tefferi A; Patnaik MM
    Leuk Lymphoma; 2017 Apr; 58(4):872-881. PubMed ID: 27687869
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
    Fend F; Horn T; Koch I; Vela T; Orazi A
    Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mutational analysis in BCR-ABL-negative classic myeloproliferative neoplasms: impact on prognosis and therapeutic choices.
    Tefferi A
    Leuk Lymphoma; 2010 Apr; 51(4):576-82. PubMed ID: 20214447
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment.
    Gotlib J; Maxson JE; George TI; Tyner JW
    Blood; 2013 Sep; 122(10):1707-11. PubMed ID: 23896413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.
    Bacher U; Schnittger S; Kern W; Weiss T; Haferlach T; Haferlach C
    Ann Hematol; 2009 Dec; 88(12):1207-13. PubMed ID: 19415278
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Myelodysplastic/myeloproliferative neoplasm with neutrophilia (atypical chronic myeloid leukemia-aCML).
    Martino G; Quintini M; Martelli MP; Ascani S; Lazzi S; Mecucci C
    Am J Hematol; 2023 Jul; 98(7):1163-1164. PubMed ID: 36594191
    [TBL] [Abstract][Full Text] [Related]  

  • 50. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia.
    Pardanani A; Lasho TL; Laborde RR; Elliott M; Hanson CA; Knudson RA; Ketterling RP; Maxson JE; Tyner JW; Tefferi A
    Leukemia; 2013 Sep; 27(9):1870-3. PubMed ID: 23604229
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Clara JA; Sallman DA; Padron E
    Cancer Biol Med; 2016 Sep; 13(3):360-372. PubMed ID: 27807503
    [TBL] [Abstract][Full Text] [Related]  

  • 52. CSF3R-mutant chronic myelomonocytic leukemia is a distinct clinically subset with abysmal prognosis: a case report and systematic review of the literature.
    Guastafierro V; Ubezio M; Manes N; Milanesi C; Della Porta M; Bonometti A
    Leuk Lymphoma; 2023 Sep; 64(9):1566-1573. PubMed ID: 37395413
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.
    Onida F; de Wreede LC; van Biezen A; Eikema DJ; Byrne JL; Iori AP; Schots R; Jungova A; Schetelig J; Finke J; Veelken H; Johansson JE; Craddock C; Stelljes M; Theobald M; Holler E; Schanz U; Schaap N; Bittenbring J; Olavarria E; Chalandon Y; Kröger N
    Br J Haematol; 2017 Jun; 177(5):759-765. PubMed ID: 28369779
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
    Kuendgen A; Kasprzak A; Germing U
    Front Oncol; 2021; 11():778741. PubMed ID: 34869027
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
    Kim SY; Song IC; Kim J; Kwon GC
    Ann Diagn Pathol; 2024 Apr; 71():152317. PubMed ID: 38642470
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.
    Ragon BK; Savona MR
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S37-S42. PubMed ID: 28760301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myelodysplastic/myeloproliferative neoplasms-unclassifiable with isolated isochromosome 17q represents a distinct clinico-biologic subset: a multi-institutional collaborative study from the Bone Marrow Pathology Group.
    Kanagal-Shamanna R; Orazi A; Hasserjian RP; Arber DA; Reichard K; Hsi ED; Bagg A; Rogers HJ; Geyer J; Darbaniyan F; Do KA; Devins KM; Pozdnyakova O; George TI; Cin PD; Greipp PT; Routbort MJ; Patel K; Garcia-Manero G; Verstovsek S; Medeiros LJ; Wang SA; Bueso-Ramos C
    Mod Pathol; 2022 Apr; 35(4):470-479. PubMed ID: 34775472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The CSF3R T618I mutation causes a lethal neutrophilic neoplasia in mice that is responsive to therapeutic JAK inhibition.
    Fleischman AG; Maxson JE; Luty SB; Agarwal A; Royer LR; Abel ML; MacManiman JD; Loriaux MM; Druker BJ; Tyner JW
    Blood; 2013 Nov; 122(22):3628-31. PubMed ID: 24081659
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and biological aspects of Philadelphia-negative/BCR-negative chronic myeloid leukemia.
    Costello R; Sainty D; Lafage-Pochitaloff M; Gabert J
    Leuk Lymphoma; 1997 Apr; 25(3-4):225-32. PubMed ID: 9168433
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ETNK1 mutation occurs in a wide spectrum of myeloid neoplasms and is not specific for atypical chronic myeloid leukemia.
    Shuai W; Zuo Z; Li N; Garces S; Jelloul FZ; Ok CY; Li S; Xu J; You MJ; Wang W; Rehder C; Jabbour EJ; Patel KP; Medeiros LJ; Yin CC
    Cancer; 2023 Mar; 129(6):878-889. PubMed ID: 36583229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.